Table 2. Contractile Responses.

(A) Responses to graded doses of exogenous Urotensin-II (U-II) in nonfailing and failing myocardium. (B) Responses to U-II receptor antagonism (UT-A) with GSK248451A at 1 μM with and without coadministration of U-II (1 μM).

A
Group	Condition	Dev F (mN/mm2)	+dF/dt (mN/s/mm2)	TPF (ms)	Dia F (mN/mm2)	−dF/dt (mN/s/mm2)
Nonfailing (n=13)	Baseline	10.5 ± 0.4	91.0 ± 5.9	191 ± 9.3	3.85 ± 0.5	66.9 ± 5.0
	0.1 nM U-II	14.6 ± 0.7 †	121 ± 9.2 †	198 ± 9.2	2.85 ± 0.4	97.9 ± 7.5 †
	1.0 nM U-II	16.5 ± 1.2 †	136 ± 10 †	196 ± 9.7	2.94 ± 0.4	102 ± 8.5 †
	10 nM U-II	15.0 ± 1.3 *	132 ± 12 †	188 ± 8.8	2.97 ± 0.3	93.6 ± 8.5 *
	100 nM U-II	14.6 ± 1.3 *	130 ± 13 †	185 ± 9.0	2.63 ± 0.4	88.1 ± 8.5
	1000 nM U-II	14.1 ± 1.2	126 ± 12 *	183 ± 15	3.06 ± 0.5	84.6 ± 7.1
Failing (n=11)	Baseline	17.2 ± 2.4	122 ± 19	235 ± 9.8	4.65 ± 0.7	89.6 ± 18
	0.1 nM U-II	16.3 ± 2.4	128 ± 22	223 ± 13	4.18 ± 0.9	94.2 ± 18
	1.0 nM U-II	14.8 ± 2.0	120 ± 21	224 ± 16	4.53 ± 1.0	79.9 ± 15
	10 nM U-II	13.7 ± 1.7	113 ± 17	224 ± 18	4.49 ± 1.0	76.8 ± 13
	100 nM U-II	12.8 ± 1.5 *	109 ± 16	210 ± 12	5.57 ± 1.2	69.0 ± 11
	1000 nM U-II	12.5 ± 1.6 *	104 ± 17	216 ± 14	5.93 ± 1.4	60.5 ± 8.5

B
Group	Condition	Dev F (mN/mm2)	+dF/dt (mN/s/mm2)	TPF (ms)	Dia F (mN/mm2)	−dF/dt (mN/s/mm2)
Nonfailing (n=9)	Baseline	13.8 ± 1.0 #	104 ± 7	220 ± 21	8.3 ± 2.7	75 ± 5 #
	UT-A	10.8 ± 1.2 #	91 ± 12	209 ± 19	6.2 ± 1.9	65 ± 8
	UT-A w/ U-II	13.2 ± 1.4	101 ± 14	231 ± 26	7.0 ± 2.0	75 ± 8
Failing (n=14)	Baseline	10.6 ± 0.4	82 ± 6	236 ± 18	5.2 ± 1.0	53 ± 3
	UT-A	14.8 ± 0.8 †	105 ± 7 †	243 ± 20	4.9 ± 1.1	74. ± 4 †
	UT-A w/ U-II	14.4 ± 1.2 †	107 ± 9 †	229 ± 15	4.8 ± 1.2	69 ± 5 *

Abbreviations: Dev F, developed force; +dF/dt, maximal rate of force generation; TPF, time to peak force; Dia F, diastolic force; −dF/dt, maximal rate of force relaxation.

^*denotes p<0.05

^†denotes p<0.01 compared with Baseline within group compared to Baseline.

^#denotes p<0.05 between groups under the same condition.